The trajectory of the erectile dysfunction drug presents a complex picture for shareholders. While the initial release generated substantial profits, the lapse of its intellectual property protection opened the floodgates to generic versions, dramatically eroding market share. This presents a particular challenge for pharmaceutical companies relyin

The legacy of Viagra, and its developer copyright, presents a intriguing case study for investors. At first a blockbuster drug, generating billions in revenue , its patent expiration created a wave of lower-priced alternatives , significantly impacting its dominance. While specific firms may attempt to capitalize on website male sexual dysfunction,